Mesenchymal stem cells for cartilage regeneration in dogs

Akari Sasaki, Mitsuru Mizuno, Manabu Mochizuki, Ichiro Sekiya

Abstract

Articular cartilage damage and osteoarthritis (OA) are common orthopedic diseases in both humans and dogs. Once damaged, the articular cartilage seldom undergoes spontaneous repair because of its avascular, aneural, and alymphatic state, and the damage progresses to a chronic and painful situation. Dogs have distinctive characteristics compared to other laboratory animal species in that they share an OA pathology with humans. Dogs can also require treatment for naturally developed OA; therefore, effective treatment methods for OA are desired in veterinary medicine as well as in human medicine. Recently, interest has grown in regenerative medicine that includes the use of mesenchymal stem cells (MSCs). In cartilage repair, MSCs are a promising therapeutic tool due to their self-renewal capacity, ability to differentiate into cartilage, potential for trophic factor production, and capacity for immunomodulation. The MSCs from dogs (canine MSCs; cMSCs) share various characteristics with MSCs from other animal species, but they show some deviations, particularly in their differentiation ability and surface epitope expression. In vivo studies of cMSCs have demonstrated that intraarticular cMSC injection into cartilage lesions results in excellent hyaline cartilage regeneration. In clinical situations, cMSCs have shown great therapeutic effects, including amelioration of pain and lameness in dogs suffering from OA. However, some issues remain, such as a lack of regulations or guidelines and a need for unified methods for the use of cMSCs. This review summarizes what is known about cMSCs, including their characteristics, their therapeutic effects in cartilage lesion treatment in preclinical in vivo studies, their clinical efficacy for treatment of naturally developed OA in dogs, and the current limitations of cMSC studies.

Key words: Mesenchymal stem cell; Dog; Cartilage; Osteoarthritis; Regenerative medicine; Veterinary medicine
Mesenchymal stem cells (MSCs) are promising therapeutic tools for treatment of cartilage damage and osteoarthritis (OA). This review summarizes the current knowledge of MSCs from dogs, including in vitro characteristics, in vivo cartilage regenerative potential, and therapeutic effects for naturally developed OA in dogs. MSCs from dogs share many in vivo characteristics with MSCs from other animal species and are reported to have excellent cartilage repair potential in experimental and clinical situations. The article also describes the current limitations of MSC use in dogs that remain to be resolved in the future.

INTRODUCTION
Articular cartilage is critical for the normal functioning of the synovial joint. The ability of cartilage to withstand high cyclic loads and to minimize surface friction on articular surfaces allows it to act as a shock absorber and a lubricator in synovial joints[1-3]. Nevertheless, articular cartilage is still subject to damage by a variety of factors, including acute trauma, degeneration, or joint diseases. Once damaged, hyaline articular cartilage shows very limited intrinsic repair potential because of its avascular, aneural, and alymphatic state. The unrepaired cartilage defects lead to pain, swelling, and deterioration in mobility and will eventually progress to osteoarthritis (OA)[4,5].

OA is a common degenerative, progressive, and painful disease in both humans[6] and dogs[7]. Nevertheless, an adequate therapy for the repair of cartilage lesions has yet to be established. A variety of surgical interventions are available in human medicine, including microfracture[8], osteochondral autografts[9], and autologous chondrocyte implantation[10]. Following microfracture, the regenerated tissue occurs as a mixed fibrocartilage tissue that is inferior in its mechanical properties to native hyaline cartilage and has poor long-term results[11]. Similarly, osteochondral autografts have limitations of graft availability and risk of donor site morbidity[12,13]. Autologous chondrocyte implantation, although it can achieve hyaline-like cartilage repair, also has some issues, including loss of the chondrocytic phenotype in monolayer culture, limited availability of chondrocytes and inadequate chondrocyte proliferative potential[14-15].

One attractive alternative source of cells for cartilage regeneration is mesenchymal stem cells (MSCs), which are readily available, possess great proliferation ability, and can differentiate into many different cell types in the body[16,17]. MSCs have been used in various applications in both human and veterinary medicine. For cartilage lesion studies, dogs are a particularly distinctive animal species as they can serve as an experimental animal model, a clinical model for human medicine, and a treatment subject. This review summarizes the in vitro data, preclinical in vivo studies, and clinical studies involving the use of MSCs for cartilage regeneration in dogs (Figure 1).

IMPORATANCE OF STUDIES ON CARTILAGE REPAIR IN DOGS
Dogs can serve as experimental or clinical models for studies on cartilage repair in humans. Although the articular cartilage is thinner in dogs than that in humans (range in humans: 1.0-2.6 mm)[18-20], this thickness is greater in medium to large breed dogs (range: 0.95-1.3 mm) than in rodent and rabbit models. This greater thickness allows the experimental creation of articular cartilage defects without causing detrimental changes in the subchondral bone[21]. In addition, unlike the other experimental animals, dogs can accept various human-type postoperative managements, including bandaging, splinting, or exercise involving (leash) walking or training on treadmills[22,23], which can prevent OA or regulate its progression after the
Figure 1 Schematic representation of the role of mesenchymal stem cells for cartilage regeneration.
Mesenchymal stem cells (MSCs) can be isolated from various types of tissues in dogs. MSCs are an attractive therapeutic tool for cartilage regeneration as they can secrete trophic factors for chondroprotection and immunosuppression, recruit endogenous cells to the damaged lesion, and differentiate into chondrocytes, thereby ameliorating the cartilage injury.

experimental interventions.

However, the use of companion animals such as dogs as experimental models for human medicine raises ethical considerations. By contrast, the use of farm animals, such as goats, sheep and pigs, as experimental animal models is less controversial[20,23,24]. These farm animals have the further advantage that their articular cartilage thicknesses are closer to those of humans and are adequate for the creation of partial- and full-thickness defects[20,23,24]. For these reasons, dogs might be superseded by goats or pigs as experimental animal models.

Nevertheless, despite the disadvantages of using dogs as experimental animal models for preclinical studies of cartilage repair, dogs have one distinctive feature that differentiates them from other animals as they naturally develop diseases that share a close analogy with human diseases, including OA[25,26] (Figure 2). Therefore, clinical studies that are performed in dogs with naturally occurring OA can provide valuable information for the treatment of human OA patients. A variety of ante mortem diagnostic monitoring protocols, such as gait and kinematic analyses[27], arthroscopic evaluation[28], and magnetic resonance imaging[29], are feasible in dogs and allow evaluation of the therapeutic effect from a variety of viewpoints. In addition, while sharing cartilage pathologies with humans, dogs also share the lifestyles of their owners, including home and exercise habits. The life expectancy of dogs is also relatively long, and dogs are subject to similar natural and environmental factors that lead to the occurrence of OA in humans, such as traumatic injuries, obesity, and aging. Many adult dogs suffer from OA, which creates a large pool of client-owned dogs that could be available for enrollment in clinical trials of potential OA treatments[30]. Although considerable interindividual variability is evident in these clinical cases when compared to purpose-bred dogs, the results are still suitable for extrapolation to human patients.

The clinical study of dogs with OA is worthwhile for both human and veterinary medicine. Dogs suffer from many cartilage pathologies that can lead to OA, such as osteochondritis dissecans and cartilage injury caused from cranial cruciate ligament failure[30,31]; therefore, the need is increasing for cartilage lesion treatment methods that can regenerate hyaline cartilage and allow recovery of the normal mechanical function of the articular cartilage. Thus, studies on cartilage regeneration in dogs have important roles in the improvement of cartilage repair treatments and can have great significance in both human and veterinary medicine.

MSC USE IN DOGS

MSCs are cells that display self-renewal capacity and have the potential for differentiation under specific conditions into other cell types, including cartilage, bone, and adipose tissue. MSCs were first identified in bone marrow derived from mice[32], but were subsequently isolated from other tissues, including adipose tissue[33], umbilical cord[34], dental pulp[35], infrapatellar fat pad[36], and synovial membrane[37]. MSCs can also be isolated and cultured from tissues obtained from various animal species, including rats[38], rabbits[39], dogs[40], cats[41], pigs[42], and horses[43], as well as
Figure 2 Radiographic findings of osteoarthritis in dogs. A: A radiographic image of the hip joint in a 8 years old Labrador retriever suffering from osteoarthritis (OA) which results from hip dysplasia; B: A radiographic image of the stifle joint in a 4 years old Shiba suffering from OA which results from cranial cruciate ligament rupture. White arrow: Osteophytes.

The International Society for Cellular Therapy (ISCT) proposed minimal criteria to define the characteristics of human MSCs: (1) Adherence to plastic in standard culture conditions; (2) Specific surface antigen expression of CD105, CD73, CD90 and lack of expression of other hematopoietic cell surface markers, including CD45, CD34, CD14 or CD11b, CD79α or CD19, HLA-DR; and (3) Multipotent differentiation potential under specific in vitro culture conditions. These criteria also serve, to a certain extent, as parameters for MSCs derived from various animal species; however, the characteristics of MSCs differ somewhat among various animal species or tissues. Therefore, the criteria for human MSCs cannot be completely extrapolated to MSCs from veterinary species.

**Isolation, expansion, and characterization of cMSCs**

MSCs from dogs (canine MSCs: cMSCs) can be isolated from wide variety of tissue sources, including bone marrow, adipose tissue, umbilical cord, muscle, infrapatellar fat pad, synovium, and synovial fluid. For research and therapeutic purposes, MSCs are needed in large numbers, so MSCs must have a high proliferation ability. Some studies have demonstrated a higher proliferation ability for cMSCs derived from adipose tissue (AD-cMSCs) than from bone marrow (BM-cMSCs). Furthermore, the colony-forming potential and proliferation ability is higher in cMSCs from synovium (Sy-cMSCs) and from infrapatellar fat pads (IF-cMSCs) than in AD-cMSCs and BM-cMSCs. Notably, further differences are observed depending on the age of the donor dogs or the passage number of cMSCs in terms of proliferation capacity. For example, Bertolo et al. have shown a greater tendency for senescence in cMSCs than in human MSCs when grown in monolayer culture. These findings suggest that the optimal culture conditions for cMSCs should be reconsidered; for instance, the inclusion of supplemental growth factors, such as fibroblast growth factor-2 (FGF-2), could increase the proliferation ability of cMSCs.

**Table 1** shows the surface marker expression of cMSCs derived from various sources. The expression of cell surface markers is one of the identification criteria for MSCs; however, the criteria used for human MSCs may not be completely compatible with those required for cMSCs because of interspecies differences and the lack of validated antibodies and controls for cMSCs. The definitive expression of surface antigens by cMSCs has not been demonstrated, and results for cMSC surface antigen expression have been contradictory among various studies. For example, high expression (> 90%) of CD90 was reported in cMSCs derived from adipose tissue and bone marrow in some studies, whereas other studies have shown low expression (< 40%) of CD90 for cMSCs derived from adipose tissue and bone marrow. Surface epitope expression has a known correlation with differentiation potential and proliferation ability as well as with stemness; therefore, further studies are needed to identify appropriate antibody sets for cMSC characterization.

**Differentiation potential of cMSCs**

Multipotent differentiation potential is one of the defined criteria proposed by ISCT and is a crucial characteristic of MSCs used in regenerative therapy. Adipogenesis, osteogenesis, and chondrogenesis in cMSC studies are validated by specific staining
| Source            | Positive marker | Negative marker | Ref            |
|-------------------|-----------------|-----------------|----------------|
| Adipose tissue    | CD90, CD44, CD73, CD105 | CD45, CD34, CD14 | Kang et al[50], 2012 |
| Bone marrow       | CD90, CD44, CD73, CD105 | CD45, CD34, CD14 |               |
| Umbilical cord    | CD90, CD44, CD73, CD105 | CD45, CD34, CD14 |               |
| Wharton's jelly   | CD90, CD44, CD73, CD105 | CD45, CD34, CD14 |               |
| Adipose tissue    | CD90, CD44      | CD45, CD34, CD146 | Kisiel et al[52], 2012 |
| Bone marrow       | CD90, CD44      | CD45, CD34, CD146 |               |
| Muscle            | CD90, CD44      | CD45, CD34, CD146 |               |
| Periosteum        | CD90, CD44      | CD45, CD34, CD146 |               |
| Adipose tissue    | CD90, CD44      | CD45, CD11b     | Sasaki et al[49], 2018 |
| Bone marrow       | CD90, CD44      | CD45, CD11b     |               |
| Synovium          | CD90, CD44      | CD45, CD11b     |               |
| Infrapatellar fat pad | CD90, CD44      | CD45, CD11b     |               |
| Adipose tissue    | CD90, CD44, CD105, CD9 | CD45, CD34, Stro-1 | Bearden et al[53], 2017 |
| Bone marrow       | CD90, CD44, CD105, CD9 | CD45, CD34, Stro-1 |               |
| Synovium          | CD90, CD44, CD105, CD9 | CD45, CD34, Stro-1 |               |
| Adipose tissue    | CD90            | -               | Reich et al[66], 2012 |
| Bone marrow       | CD90            | -               |               |
| Adipose tissue    | CD90, CD44, CD29 | CD45, CD34     | Takemitsu et al[67], 2012 |
| Bone marrow       | CD90, CD44, CD29 | CD45, CD34     |               |
| Adipose tissue    | CD90, CD44, MHCI | CD45, CD34, CD29, CD14, MHCI | Screven et al[68], 2014 |
| Bone marrow       | CD90, CD44, MHCI | CD45, CD34, CD29, CD14, MHCI |               |
| Adipose tissue    | CD90, CD44      | CD45, CD34, CD14 |               |
| Bone marrow       | CD90, CD44      | CD45, CD34, CD14 |               |
| Adipose tissue    | CD90, CD44, CD29, CD73, CD4, CD8, MHCI | CD45, CD34, CD14, MHCI | Russell et al[69], 2016 |
| Bone marrow       | CD90, CD44, CD29, CD73, CD4, CD8, MHCI | CD45, CD34, CD14, MHCI |               |
| Adipose tissue    | CD90, CD44, MHCI | CD45, CD34, CD14, CD3, CD4, CD8, CD172a, CD11c, HLA-DR, slgM | Kang et al[70], 2008 |
| Adipose tissue    | CD90, CD44, CD29 | CD45, CD34, CD117, CD13 CD105, CD73 | Vieira et al[71], 2010 |
| Bone marrow       | CD90, CD44, CD29, CD73, CD4, CD8, MHCI | CD45, CD34, CD14, MHCI |               |
| Bone marrow       | CD90, MHCI      | CD45, CD34, MHCI | Martinello et al[72], 2011 |
| Bone marrow       | CD90, CD105     | CD45, CD34     | Kamishina et al[73], 2006 |
| Bone marrow       | CD44, Stro-1    | CD45, CD34     | Csaki et al[74], 2007 |
| Bone marrow       | CD90, CD14      | CD14           | Hodgkins-Geere et al[75], 2012 |
| Bone marrow       | CD90, CD105, CD73, CD166, vimentin | CD31 | Bertolo et al[76], 2015 |
| Bone marrow       | CD90, CD44, CD29, CD105, CD166 | CD45, CD34 | Zhang et al[77], 2018 |
| Synovium          | CD90, CD44      | -              | Li et al[78], 2018 |
| Synovial fluid    | CD90            | CD45, CD34     | Wijekoon et al[79], 2017 |

or analysis of mRNA expression (Figure 3 and Table 2).

In vitro adipogenesis of cMSCs has been confirmed for AD-cMSCs, BM-cMSCs, Sy-cMSCs, and IF-cMSCs (Table 2). The formation of oil lipid droplets is verified with oil red-O staining; however, cMSCs sometimes cannot sufficiently differentiate into adipocytes in the induction medium used for adipogenic differentiation of human MSCs, so the induction media need to be optimized for cMSCs. Neupane et al[80] utilized rabbit serum, rosiglitazone, and a higher glucose concentration in their medium to promote the adipogenic differentiation of AD-cMSCs. The optimized induction medium increased the numbers and sizes of fat globules and the expression of adipogenic transcription factors, such as PPARγ2, when compared to the conventional adipogenic differentiation medium used for human MSCs[68]. A higher adipogenic differentiation ability has been reported for AD-cMSCs and IF-cMSCs than for BM-cMSCs and Sy-cMSCs[32,43,49].
During osteogenic differentiation, the morphology of cMSCs progresses from a fibroblast-like shape to a cuboidal-like appearance, together with the formation of aggregates that stain with von Kossa or alizarin red stains. Unlike human MSCs, cMSCs have been known to roll up into a sheet and become easily detached from culture dishes during mineralization assays. BM-cMSCs have shown superiority in osteogenic differentiation in some studies, when compared to AD-cMSCs, Sy-cMSCs, and IF-cMSCs. However, Kang et al. showed a greater osteogenic ability of AD-cMSCs when compared with BM-cMSCs and Wharton’s jelly-derived cMSCs.

The chondrogenic differentiation potency is a crucial characteristic of cMSCs intended for use in cartilage regenerative therapy. In vivo cartilage formation during embryogenesis is initiated by condensation of cells, and the cell-to-cell contacts
induced by condensation are crucial for the onset of chondrogenesis\cite{69}. The growth factor transforming growth factor-β (TGF-β) is crucial for the formation of three-dimensional aggregates during chondrogenesis in human MSCs\cite{70}, whereas cMSCs intrinsically aggregate in micromass culture even in the absence of TGF-β\cite{52,68}. Nevertheless, some studies have reported difficulties in attaining substantial chondrogenic differentiation of cMSCs\cite{52,56,57,60}.

Since no definitive methods have been established for chondrogenic differentiation of cMSCs, the various studies have all used different tissue source origins, growth factors, and culture methods. The chondrogenic differentiation potential of cMSCs varies with the tissue source origin, as indicated by the larger cartilage pellets obtained from differentiating Sy-cMSCs and IF-cMSCs than from differentiating BM-cMSCs and AD-cMSCs\cite{40,53}. The cartilage pellets that differentiate from BM-cMSCs are small, but they show intense staining with toluidine blue, alcin blue, or collagen type II antibody when compared to cartilage pellets differentiated from Sy-cMSCs, IF-cMSCs, or AD-cMSCs\cite{40,53}. Conversely, AD-cMSCs, despite their abundance and ready availability, form only small cartilage pellets that show low stainability with toluidine blue, alcin blue, or collagen type II antibody and that sometimes show signs of necrosis\cite{40,56}. Human Sy-MSCs and BM-MSCs are also known to have higher chondrogenic differentiation capacity when compared with AD-MSCs\cite{44,71,72}. Interestingly, Bertolo et al\cite{73} showed that cMSCs from different dog breeds can also vary in their differentiation potential.

Chondrogenic differentiation can be enhanced in vitro by supplementing the culture medium with growth factors, such as TGF-β and bone morphogenic protein (BMP). TGF-β, which is crucial for chondrogenic differentiation of MSCs, exists as three isoforms: TGF-β1, TGF-β2, and TGF-β3. Of these, TGF-β1\cite{48,52,56,61} or TGF-β3\cite{47,49,57} have been the most commonly used in studies of chondrogenesis in cMSCs. TGF-β3 is reported to result in higher and more rapid chondrogenic differentiation in human MSCs\cite{74}, but the optimal TGF-β isoform for chondrogenesis in cMSCs remains to be elucidated.

BMPs have been reported to promote chondrogenesis\cite{75}, and a greater stimulation of chondrogenesis in human MSCs has been reported for BMP-2 than for BMP-4 or BMP-6\cite{41}. In addition to promoting chondrogenesis, BMPs can also stimulate endochondral ossification\cite{10}. Many studies of cMSCs have shown the efficacy of BMPs for osteogenesis\cite{78}, although one study reported no improvement in chondrogenesis by BM-cMSCs or AD-cMSCs\cite{56} in response to BMP-2. Therefore, the effectiveness of BMPs at inducing chondrogenesis in cMSCs remains unclear.

Chondrogenic differentiation ability decreases with the loss of CD90 in human MSCs\cite{79,80} and cMSCs\cite{55}, indicating the importance of surface epitope expressions. Therefore, the initial cell selection may improve the chondrogenic potential of MSCs. The in vitro expansion of human MSCs, rabbit MSCs, and cMSCs in culture also impairs chondrogenic differentiation potential\cite{41,44,81}. Moreover, senescence is reportedly more rapid in cMSCs than in human MSCs, particularly after passage 3\cite{44}. Sekiya et al\cite{14} reported that cartilage pellets were larger, stained more extensively for proteoglycans, and expressed higher levels of mRNA for type II procollagen when prepared from cultures enriched with small and rapidly self-renewing cells than from cultures containing more mature and slowly replicating cells. The smaller and more rapidly proliferating cells can be produced using FGF-2 during monolayer culture of cMSCs\cite{14}. FGF-2 preconditioning of cMSCs also improved their chondrogenic differentiation potential\cite{14} in a similar fashion to that observed for human MSCs\cite{14}. Therefore, it is worthwhile to consider the use of FGF-2 preconditioning for cMSC expansion, as well as the use of cMSCs at early passages, for cartilage regenerative
therapy.

**IN VIVO STUDY OF CARTILAGE REGENERATION WITH cMSCs**

While in vitro studies provide a substantial amount of information about the potential of MSCs for cartilage repair, evaluation of the in vivo behavior and function of these cells is also required. In vivo studies of cMSCs for cartilage regeneration have involved the use of surgically induced cartilage defect models, including partial-thickness cartilage defect models[86-87] (Figure 4A), full-thickness cartilage defect models[88,89] (Figure 4B) and cranial cruciate ligament transection models[90]. (Table 3) In every model, intraarticular autologous or allogeneic cMSC injection demonstrated excellent regenerative effects, including hyaline-like cartilage regeneration, when compared with control groups.

El-Tookey et al[88] reported that earlier injections of BM-cMSCs (i.e., one day after creating the chondral defect) resulted in hyaline cartilage regeneration in the defect area, whereas the therapeutic effect of a later injection (i.e., one month after creating the chondral defect) was limited to fibro-hyaline cartilage regeneration[86]. Similar results were reported for AD-cMSCs[89]. These findings suggest that injured tissue may express specific receptors or ligands that promote the adhesion or infiltration of MSCs to the defect site in the early phase of injury and that these receptors or ligands may be down-regulated as time progresses after the injury.

Mokbel et al[91] showed the homing of cMSCs in dog stifle joints with a partial thickness chondral defect after intraarticular injection of autologous AD-cMSCs labelled with green fluorescent protein. They detected labelled cells in the neocartilage at 8 wk after the cMSC injection[92]. Koga et al[91] showed that human synovial MSCs attached to the chondral defect in knee joints of humans and rabbits after placement of an MSC suspension on the defect for 10 min, and the MSCs that attached to the chondral defect expressed several adhesion molecules[91]. Injected MSCs could also be detected in the neocartilage tissue at 8 wk after injection in a rabbit osteochondral defect model, however, no labeled MSCs could be detected at 12 wk[92]. Most of the MSCs injected into synovial joints migrate into the synovial membrane, in addition to the articular cartilage, in rat OA model[93] and in normal or OA horses[94]. After migration to the synovium, the MSCs maintain their MSC properties, without differentiating into another lineage, for at least 28 d. Meanwhile, they secrete several trophic factors, such as PRG-4, BMPs, and TSG-6, which are the key trophic factors for chondroprotection and immunosuppression[95]. Thus, in early phase of cartilage injury, intraarticularly injected MSCs may migrate into the chondral defect and regenerate neocartilage tissue, while most of the residual MSCs migrate into the synovium in the joints and produce trophic factors that provide chondroprotective and immunosuppressive effects. The immunomodulatory effects of cMSCs in dog joints have also been confirmed in several studies[94,95].

Some studies have demonstrated greater repair effects, determined by histological evaluation of chondral defects, for intraarticular injections of cMSCs in combination with either hyaluronic acid[86,87] or platelet-rich plasma[96] when compared with injection of cMSCs alone. Therefore, some synergistic effects of cMSCs are expected when used in combination with chondroprotective materials.

**CLINICAL APPLICATIONS OF cMSCs FOR CARTILAGE INJURY AND OA**

Conventional OA therapies in dogs include drug therapy, weight loss regimens, exercise programs, nutraceuticals, and supplements[97]. The objectives of these treatment methods are to minimize joint pain, reduce inflammation, and restrain the progression of the cartilage damage; however, they often do not provide complete pain relief[98,99]. MSCs are a promising therapeutic tool for OA as they can secrete trophic factors[90,99], recruit endogenous cells to the damaged lesion[99,100], and differentiate into chondrocytes[93], thereby ameliorating the cartilage injury. Several clinical studies have utilized cMSCs for OA in dogs, with most treating OA with AD-cMSCs (Table 4).

Dogs in actual conditions of OA can serve as vulnerable translational animal models for human medicine in terms of the use of MSCs. Each cMSC study has demonstrated improvement in OA symptoms after single intraarticular, intravenous, or acupuncture point injections of cMSCs. Some studies have injected cMSCs in
Table 3 In vivo study of canine mesenchymal stem cells for cartilage repair

| Source          | Injection / transplantation | Combination use | Cell number (million) | Model                        | Evaluation method                                      | Ref.            |
|-----------------|------------------------------|-----------------|-----------------------|------------------------------|--------------------------------------------------------|-----------------|
| Bone marrow     | Single intraarticular, autologous | -               | 7-8                   | Partial thickness articular cartilage defect | Histology                                              | El-Tookhy et al.[90], 2008 |
| Adipose tissue  | Single intraarticular, autologous | -               | 7-8                   | Partial thickness articular cartilage defect | Morphology, histology, fluorescence analysis          | Mokbel et al.[87], 2011 |
| Adipose tissue  | Four times intraarticular, allogeneic | 5 (three times), 66 (once) | Intact                | Pain and lameness scoring, immunohistochemistry      | Park et al.[91], 2013 |
| Bone marrow     | Transplantation with scaffold, allogeneic | Scaffold       | 0.01                  | Full-thickness cartilage defect                  | Histology, immunohistochemistry, micro CT             | Duan et al.[90], 2013 |
| Synovium        | Single intraarticular, autologous | Hyaluronic acid | 0.05, 5 or 50         | Partial thickness articular cartilage defect       | Histology                                              | Miki et al.[88], 2015 |
| Adipose tissue  | Single intraarticular, allogeneic | Platelet-rich plasma | 10                    | Cranial cruciate ligament transaction             | Lameness scoring, focal compression strength, extracellular matrix composition, histopathology, real-time PCR | Yun et al.[94], 2016 |
| Bone marrow     | Single intraarticular, allogeneic | Hyaluronic acid | 10                    | Partial thickness articular cartilage defect       | Gross appearance, magnetic resonance imaging, histology, immunohistochemistry | Li et al.[83], 2018 |
| Umbilical cord  | Single intraarticular, allogeneic | -               | 1                     | Surgical manipulation of articular cartilage       | Magnetic resonance imaging, radiography, ultrasonography, blood test, scanning electron microscope | Zhang et al.[93], 2018 |

Improvements in pain, lameness, and range of motion were observed from 1 week[10,20] after the cMSC injection up to 180 d after cMSC injection alone[89] or up to 12 mo after cMSC injection in combination with hyaluronic acid[10]. However, one report showed a decrease in the effects of cMSCs between 30 and 90 d after the cMSC intraarticular injection[89]. Since the number of cells is known to decrease rapidly after administration of MSCs into the stifle joint[89], longer lasting effects of cMSCs might be obtained by periodic injections.

Most of the clinical studies have used subjective evaluation methods, including pain, lameness, range of motion, and functional disability scoring or owner questionnaires, while two studies provided objective evaluations with gait analysis using a force platform[51,63]. Assessing pain in an objective manner is important, especially in nonverbal patients, and gait analysis with a force platform is a valuable method that offers repeatable and quantitative measurements of ground reaction force from the feet of the dog[10]. However, the objective measures cannot provide information on some features, such as activity level, reluctance to run in dogs, and regeneration of damaged articular cartilage. Therefore, multi-aspect evaluation is needed for the measurement of cMSC effects. One study by Kriston-Pál et al.[89] utilized arthroscopic and histological evaluation in addition to owners’ questionnaires and demonstrated that the repaired articular cartilage in the cMSC-treated joint consisted of hyaline-like cartilage.

The immunomodulatory effect of BM-cMSCs was demonstrated by Muir et al.[88] for dog stifles with cranial cruciate ligament rupture. Intraarticular and intravenous injection of autologous BM-cMSCs in dogs with partial rupture of the cranial cruciate ligament suppressed systemic and stifle joint inflammation, including C-reactive protein concentrations and circulating CD8+ T lymphocyte number.

No serious adverse events have been reported in the clinical studies using intraarticular injection, acupuncture point injection, and intravenous injection of cMSCs. Nevertheless, Kang et al.[111] indicated that the development of pulmonary...
edema and hemorrhage are possible adverse reactions following intravenous injections of cMSCs. Therefore, dogs treated with cMSC transplantation should be observed cautiously after injection.

**DISCUSSION**

This is the first review of cMSC isolation, characterization, differentiation, and use in *in vivo* models for cartilage repair and clinical trial for cartilage diseases. The cMSCs can be isolated from various tissues in the body, and the cMSCs derived from each tissue have specific characteristics. Although the cMSCs used in most studies at least partially meet the criteria for human MSCs declared by ISCT, suitable surface epitopes for cMSCs have not yet been established. cMSCs can differentiate into adipocytes, osteocytes, and chondrocytes *in vitro*; however, the differentiation methods differ among studies, and some studies have reported difficulties in inducing chondrogenic differentiation. Thus, suitable differentiation protocols for cMSCs should be identified to ensure sufficient differentiation in *in vitro* studies.

Dogs can serve as an experimental animal model for studies on cartilage repair, and cMSCs can lead to hyaline cartilage repair of experimentally created cartilage defects *in vivo*. Although dogs have a variety of unique characteristics compared to other experimental animals, they also share some problems, including body size and ethical concerns. For these reasons, farm animals, including pigs, sheep, and goats, can supersede dogs as experimental animal models for human medicine.

One distinctive feature of dogs is that many dogs naturally develop OA during their lives, which means that clinical trials can be performed. The results of clinical studies have proved the great cartilage regenerative and immunomodulatory effects of cMSCs in veterinary patient dogs with OA. Since the current therapeutic objective for OA treatment in both human and veterinary patients is management of pain and functional recovery of joints\(^{[112]}\), the results of clinical studies in dogs can provide significant information for the treatment of cartilage lesions in both human and veterinary medicine. However, it should be noted that cell therapies in veterinary patients are not strictly supervised by regulatory agencies in most countries\(^{[113]}\). Regulations and guidelines for the use of MSCs in veterinary medicine are still urgently required. In addition, dogs cannot communicate the presence or degree of pain in diagnostic or therapeutic effect measurement phases, so caution is required in interpreting the results of studies using veterinary MSCs.

In stifle joints, meniscus damage is also known to induce and progress cartilaginous damage in dogs and humans\(^{[114-116]}\), and the meniscal tear is one of the most prevalent injuries in the stifle joint\(^{[115,117]}\). Therefore, the effectiveness of cMSC treatments for meniscal injury as well as chondral lesions is expected to be elucidated in the future.

**CONCLUSION**

In recent years, expectations have increased regarding the use of MSCs in both human and veterinary medicine, and many *in vitro* or *in vivo* studies support the therapeutic effects of cMSCs for treatment of cartilage lesions and OA in dogs. Dogs can serve as clinical models as well as experimental animal models for human medicine, while...
Table 4 Clinical study of canine mesenchymal stem cells for osteoarthritis in dogs

| Source          | Injection                                                   | Cell number (million) | Target joint | Observation period | Evaluation points                                                                 | Ref.             |
|-----------------|-------------------------------------------------------------|-----------------------|--------------|--------------------|----------------------------------------------------------------------------------|-----------------|
| Adipose tissue  | Single intraarticular, autologous                           | 4.2-5                 | Hip          | 30, 60, 90 d       | Lameness, pain, range of motion, functional disability, owner questionnaire       | Black et al[121], 2007 |
| Adipose tissue  | Single intraarticular, autologous                           | 3-5                   | Elbow        | 30, 60, 90, 180 d  | Lameness, pain, range of motion, functional disability, owner questionnaire       | Black et al[107], 2008 |
| Adipose tissue  | Single intraarticular with platelet-rich plasma or hyaluronic acid, autologous | 3-5                   | Elbow        | 1 wk, 1 mo         | Not described                                                                      | Guercio et al[103], 2012 |
| Adipose tissue  | Single intraarticular with platelet-rich plasma, autologous | Over 30               | Hip          | 0, 30, 90, 180 d   | Gait analysis                                                                      | Vilar et al[104], 2013 |
| Adipose tissue  | Single intraarticular, autologous                           | 30                    | Hip          | 1, 3, 6 mo         | Pain, functional disability, range of motion, owner questionnaire                  | Cuervo et al[21], 2014 |
| Adipose tissue  | Single intraarticular, autologous                           | 15                    | Hip          | 0, 30, 90, 180 d   | Gait analysis                                                                      | Vilar et al[104], 2014 |
| Adipose tissue  | Acupoint injection, allogeneic                              | 0.2-0.8               | Hip          | 7, 15, 30 d        | Pain, functional disability, range of motion                                       | Marx et al[91], 2014 |
| Adipose tissue  | Single intraarticular, allogeneic                           | 12                    | Hip, elbow, stifle, shoulder | 60 d     | Pain, owner questionnaire                                                         | Harman et al[23], 2016 |
| Bone marrow     | Single intraarticular and single intravenous, autologous    | 5 for intraarticular, 2 for intravenous | Stifle     | 4, 8 wk            | Circulating T lymphocyte, C reactive protein and cytokine concentration, total cell count in synovial fluid | Muir et al[98], 2016 |
| Adipose tissue  | Single intraarticular with hyaluronic acid, allogeneic      | 12                    | Elbow        | 6, 9, 12 mo        | Owner questionnaire, arthroscopic image, histology                                 | Kristen-Pál et al[30], 2017 |
| Adipose tissue  | Single intraarticular and/or single intravenous, allogeneic | Not described         | Various joints | 10 wk             | Lameness, pain, range of motion, functional disability                             | Shah et al[99], 2018 |

they themselves, as veterinary patients, require effective treatment methods for cartilage lesions and OA. Thus, despite several limitations and problems, including ethical issues and difficulty of effect measurement, studies of MSCs in dogs have great significance from various points of view. Regulations and guidelines for cMSCs should be established in the future, and standardized methods for cMSC usage would provide more unified and reliable results from the studies. More data on cMSC characteristics and their use as an OA treatment in dogs will be needed, and they must be meaningful for the improvement of cartilage repair treatment in both human and veterinary medicine.

ACKNOWLEDGEMENTS

We thank Ms. Ellen Roider for English editing.

REFERENCES

1 Bonnevie ED, Galesso D, Secchiere C, Bonassar LJ. Degradation alters the lubrication of articular cartilage by high viscosity, hyaluronic acid-based lubricants. J Orthop Res 2018; 36: 1456-1464 [PMID:
Subchondroplasty for the treatment of post-traumatic bone marrow lesions of the medial femoral condyle, Bozynski CC, Cook CR, Kuroki K, Sherman SL, Pfeiffer FM, Stoker AM, Cook JL.

10.1016/j.vaa.2017.07.008

naturally occurring osteoarthritis.

2017; 44: 1709-1729 [PMID: 27066619 DOI: 10.1002/stem.2377]

342018; Osteoarthritis Cartilage: 730-740 [PMID: 29580978 DOI: 10.1016/j.joca.2018.03.006]

30391394 DOI: 10.1016/j.joca.2018.09.016

30599134 DOI: 10.1007/s00167-019-05359-9

30871236 DOI: 10.1039/c8bio00103a

30395060 DOI: 10.1017/jos.2016.0000000226

30971342 DOI: 10.1097/JSAA.0000000000001215

302641 [PMID: 29535784 DOI: 10.1016/j.joca.2018.11.008]

30054536 DOI: 10.1016/j.jpubintmed.2018.10.023

29443563 DOI: 10.1016/j.jpubintmed.2018.10.023

1582-1587 [PMID: 27015600 DOI: 10.1016/art.36992]

1325-1332 [PMID: 26798997 DOI: 10.1517/14712598.2016.1145651]

1373-1381 [PMID: 29167071 DOI: 10.1016/j.vaa.2017.11.021]

12891 DOI: 10.1186/s40634-016-0066-0

230 [PMID: 27229835 DOI: 10.1186/s12911-016-1085-9]

20545621 DOI: 10.1377/ajhp.heww07

20618832 DOI: 10.1038/s41550-018-13940-6

20586007 DOI: 10.1186/s40634-016-0037-x

2040

204606 DOI: 10.1016/j.actbio.2017.11.021

20510326 DOI: 10.1186/s13028-016-4265-9

204606/javma.225.2.701

205904855 DOI: 10.1246/javma.252.6.701

20250106 DOI: 10.1186/s13258-016-0766-4

205904878 DOI: 10.1186/s41598-018-0066-0

20586007 DOI: 10.1186/s40634-016-0037-x

20586007 DOI: 10.1186/s40634-016-0037-x

204606/javma.225.2.701

205904855 DOI: 10.1246/javma.252.6.701

20250106 DOI: 10.1186/s13258-016-0766-4

205904878 DOI: 10.1186/s41598-018-0066-0

20586007 DOI: 10.1186/s40634-016-0037-x

204606/javma.225.2.701

205904855 DOI: 10.1246/javma.252.6.701
in a pre-clinical canine model. J Orthop Res 2018; 36: 2709-2717 [PMID: 29748965 DOI: 10.1002/jor.24046]

29 Ren J, Ma J, Zhang X, Aimaiti A, Saiziti M, Chen Y, Cao L. Diagnostic value of combined serum marker changes and quantitative MRI evaluation of cartilage volume of tibial plateau in a surgically-induced osteoarthritis dog model. J Int Med Res 2017; 45: 2023-2035 [PMID: 29125013 DOI: 10.1177/0300060517730452]

30 Egan P, Murphy S, Jovanovik J, Tucker R, Fitzpatrick N. Treatment of osteochondrosis dissecans of the canine stifle using synthetic osteochondral resurfacing. Vet Comp Orthop Traumatol 2018, 31: 144-152 [PMID: 29234283 DOI: 10.3415/vcot-17-02-0035]

31 Cachon T, Frykman O, Innes JF, Lascelles BDX, Okumura M, Sousa P, Staffieri F, Steagall PV, Van Ryssen B. COAST Development Group. Face validity of a proposed tool for staging canine osteoarthrosis: Canine OsteoArthritis Staging Tool (COAST). Vet J 2018; 235: 1-8 [PMID: 29704933 DOI: 10.1016/j.tvjl.2018.02.017]

32 Friedenstein AJ, Platenkzy-Shapiro II, Petrukova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16: 381-390 [PMID: 5336210]

33 Zuck PA, Zhu M, Mizuno H, Huang J, Futtrel JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-226 [PMID: 11304560 DOI: 10.1089/10763770160028599]

34 Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003; 21: 105-110 [PMID: 12592557 DOI: 10.1634/stemcells.21-1-105]

35 Grutherford S, Mankani M, Ibrahim J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci U S A 2000; 97: 13656-13650 [PMID: 11087920 DOI: 10.1073/pnas.240309797]

36 Wickham MQ, Erickson GR, Gimble JM, Vail TP, Gulak F. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop Relat Res 2003; 196-212 [PMID: 12838072 DOI: 10.1097/01.blo.0000072467.57786.ca]

37 De Bari C, Dell’Acio F, Tydzianowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928-1942 [PMID: 11504846 DOI: 10.1002/1529-0131(200104)44:8<1928::AID-ART331>3.0.CO;2-P]

38 Yoshimura H, Muneta T, Nimura A, Yokoyama A, Koga H, Sekiya I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, peristeous, adipose tissue, and muscle. Cell Tissue Res 2007; 327: 449-462 [PMID: 17032990 DOI: 10.1007/s00441-006-0570-6]

39 Khalilifar MA, Baghavam ESLamimnejad MR, Ghaseemzadeh M, Hosseini S, Baharavand H. In vitro and in vivo comparison of different types of rabbit mesenchymal stem cells for cartilage repair. Cell J 2019; 21: 150-160 [PMID: 30822588 DOI: 10.2074/cellj.2019.6149]

40 Sasaki A, Mizuno M, Oikuri N, Kataho H, Otobe K, Tsujii K, Koga H, Mochinuki M, Sekiya I. Canine mesenchymal stem cells from synovium have a higher chondrogenic potential than those from infrapatellar fat pad, adipose tissue, and bone marrow. PLoS One 2013; 8: e6020922 [PMID: 30138399 DOI: 10.1371/journal.pone.0202922]

41 Quimby JM, Borjeson DL. Mesenchymal stem cell therapy in cats: Current knowledge and future potential. J Feline Med Surg 2018; 20: 208-216 [PMID: 29478398 DOI: 10.1177/1098612X18758590]

42 Bharti D, Shikavkumar SB, Subbarao RB, Rho GJ. Research Advancements in Porcine Derived Mesenchymal Stem Cells. Curr Stem Cell Res Ther 2016; 11: 78-93 [PMID: 26201864 DOI: 10.2174/1574888X10666150723145911]

43 Zayed M, Camigli C, Misk N, Dhar MS. Donor-matched comparison of chondrogenic potential of equine bone marrow- and synovial fluid-derived mesenchymal stem cells: implications for cartilage tissue regeneration. Front Vet Sci 2017; 3: 121 [PMID: 28199840 DOI: 10.3389/fvets.2016.00121]

44 Fellows CR, Matta C, Zakany R, Khan IM, Mobasheri A. Adipose, bone marrow and synovial joint-derived mesenchymal stem cells for cartilage repair. Front Genet 2016; 7: 213 [PMID: 28066501 DOI: 10.3389/fgene.2016.00213]

45 Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marin M, Krause D, Reams D, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317 [PMID: 16923606 DOI: 10.1080/14634200608590050]

46 Cascio C, Matsu-U, Mobasheri A, Ye H, Shikhaibaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study. Histochem Cell Biol 2007; 128: 507-520 [PMID: 17922135 DOI: 10.1007/s00418-007-0337-z]

47 Zhang S, Zhao C, Liu S, Wang Y, Zhao Y, Guan W, Zha Z. Characteristics and multilineage differentiation of bone marrow mesenchymal stem cells derived from the Tibetan mastiff. Mol Med Rep 2018; 18: 2097-2109 [PMID: 29916546 DOI: 10.3892/mmr.2018.9172]

48 Vieira NM, Brandalise V, Zuconci E, Secco M, Strauss BE, Zatz M. Isolation, characterization, and differentiation potential of canine mesenchymal stem cells. Cell Transplant 2010; 19: 279-289 [PMID: 19995482 DOI: 10.3727/096368910X514816764]

49 Screven R, Kenyon E, Myers MJ, Yance H, Skasko M, Boxer L, Bigley EC, Borjeson DL, Zhu M. Immunophenotype and gene expression profile of mesenchymal stem cells from canine adipose tissue and bone marrow. Vet Immunol Immunopathol 2014; 161: 21-31 [PMID: 25026887 DOI: 10.1016/j.vetimm.2014.06.002]

50 Kang BJ, Ryu HJ, Park SS, Koyama Y, Kikuchi M, Woo HM, Kim WH, Kweon OK. Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose tissues, bone marrow, umbilical cord blood, and Wharton's jelly for treating bone defects. J Vet Sci 2012; 13: 299-310 [PMID: 23006587 DOI: 10.4142/jvets.2012.13.3.299]

51 Zhang BY, Wang BY, Li SC, Luo DZ, Zhan X, Chen SF, Chen ZJ, Liu CY, Ji HQ, Bai YS, Li DS, He Y. Evaluation of the curative effect of umbilical cord mesenchymal stem cell therapy for knee arthritis in dogs using imaging technology. Stem Cells Int 2018; 2018: 1983025 [PMID: 29601739 DOI: 10.1155/2018/1983025 DOI: 10.1002/jbmr.26887 DOI: 10.2466/gene.738.1305]

52 Kisiel AH, McDuffee LA, Masaeud E, Bailey TR, Esparza Gonzalez BP, Nino-Fong R. Isolation, characterization, and in vitro proliferation of canine mesenchymal stem cells derived from bone marrow, adipose tissue, muscle, and periosteum. Am J Vet Res 2012; 73: 1305-1317 [PMID: 22849692 DOI: 10.2466/gene.738.1305]

53 Bearden RN, Huggins SS, Cummings KJ, Smith R, Gregory CA, Saunders WB. In-vitro characterization
of canine multipotent stromal cells isolated from synovium, bone marrow, and adipose tissue: a donor-matched comparative study. Stem Cell Res Ther 2017; 8: 218 [PMID: 28974260 DOI: 10.1186/s13287-017-0639-6]

54 Wijекoon HMS, Toyota K, Kim S, Fang J, Bwalya EC, Hosoya K, Okumura M. Differentiation potential of synoviocytes derived from joints with cranial cruciate ligament rupture and medial patella luxation in dogs. Rev Vet Sci 2017; 114: 370-377 [PMID: 28718189 DOI: 10.1016/j.rvsc.2017.07.004]

55 Krawetz RJ, Wu YE, Martin L, Rattner JB, Matyas JR, Hart DA. Synovial fluid progenitors expressing CD90+ from normal but not osteoarthritic joints undergo chondrogenic differentiation without micro-mass culture. PLoS One 2012; 7: e3616 [PMID: 2275723 DOI: 10.1371/journal.pone.0036161]

56 Reich CM, Raabe O, Wenisch S, Bridger PS, Kramer M, Arnhold S. Isolation, culture, and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal stem cells—a comparative study. Vet Res Commun 2012; 36: 139-148 [PMID: 22392958 DOI: 10.1007/s11259-012-9523-0]

57 Russell KA, Chow NH, Dukoff D, Gibson TW, LaMarre J, Betts DH, Koch TG. Characterization and immunomodulatory effects of canine adipose tissue- and bone marrow-derived mesenchymal stem cells. PLoS One 2016; 11: e0167442 [PMID: 27907211 DOI: 10.1371/journal.pone.0167442]

58 Guercio A, Di Bella S, Casella S, Di Marco P, Russo C, Piccione G. Canine mesenchymal stem cells (MSCs): characterization in relation to donor age and adipose tissue-harvesting site. Cell Biol Int 2013; 37: 789-798 [PMID: 23595103 DOI: 10.1002/cib.10090]

59 Volk SW, Wang Y, Hankenson KD. Effects of donor characteristics and ex vivo expansion on canine mesenchymal stem cell properties: implications for MSC-based therapies. Cell Transplant 2012; 21: 2189-2200 [PMID: 22472645 DOI: 10.3727/096369912x636821]

60 Bertolus A, Schlaflai P, Malonzo-Marty C, Baar M, Pötzel T, Steffen F, Stoyanov J. Comparative characterization of canine and human mesenchymal stem cells derived from bone marrow. Int J Stem Cell Res 2015; 2: 1 [DOI: 10.23937/2469-570X/1410005]

61 Endo K, Fujita N, Nakagawa T, Nishimura R. Effect of fibroblast growth factor-2 and serum on canine mesenchymal stem cell chondrogenesis. Tissue Eng Part A 2018 [PMID: 30319056 DOI: 10.1089/ten.TEA.2018.0177]

62 Kang JW, Kang KS, Koo HC, Park JR, Choi EW, Park VH. Soluble factors-mediated immunomodulatory effects of canine adipose tissue-derived mesenchymal stem cells. Stem Cells Dev 2008; 17: 681-693 [PMID: 18717642 DOI: 10.1086/287072]

63 Li L, Duan X, Fan Z, Chen L, Xing F, Xu Z, Chen Q, Xiang Z. Mesenchymal stem cells in combination with hyaluronic acid for articular cartilage defects. Sci Rep 2018; 8: 9900 [PMID: 29967404 DOI: 10.1038/s41596-018-27737-y]

64 Takemitsu H, Zhao D, Yamamoto I, Harada Y, Michishita M, Arai T. Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res 2012; 8: 150 [PMID: 22937862 DOI: 10.1186/1746-6148-8-150]

65 Martinello T, Bronzini I, Mascatrollo L, Mollo A, Sampaolesi M, Decamandria M, Panattoni M. Canine adipose-derived mesenchymal stem cells do not lose stem features after a long-term cryopreservation. Rev Vet Sci 2011; 91: 18-24 [PMID: 20732703 DOI: 10.1016/j.rvsc.2010.07.024]

66 Kocan B, Maziarz A, Tabarkiewicz J, Ochiya T, Banasi-Zabczak A. Trophic activity and phenotype of adipose tissue-derived mesenchymal stem cells as a background of their regenerative potential. Stem Cells Int 2017; 2017: 163234 [PMID: 29757877 DOI: 10.1155/2017/1632345]

67 Mo M, Wang S, Zhou Y, Li H, Wu Y. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. Cell Mol Life Sci 2016; 73: 3311-3321 [PMID: 27141940 DOI: 10.1007/s00018-016-2229-7]

68 Neupane M, Chang CC, Kuipeol M, Yuzbasiyan-Gurkan V. Isolation and characterization of canine adipose-derived mesenchymal stem cells. Tissue Eng Part A 2008; 14: 1007-1015 [PMID: 19230125 DOI: 10.1089/tca.2007.0207]

69 Allas L, Boumédiène K, Baugé C. Epigenetic dynamic during endochondral ossification and articular cartilage development. Bone 2019; 120: 523-532 [PMID: 30296494 DOI: 10.1016/j.bone.2018.10.004]

70 Omar SNC, Goh BS, Ubaishal MA, Khairiyo KJ, Salaiaman S, Saim L, Chun KH. Transforming growth factor beta 3 induced human adipose-derived stem cells for articular chondrogenesis. Sains Malays 2018; 47: 2349-2358 [DOI: 10.17576/bsm-2018-4710-11]

71 Garcia J, Mennan C, McCarthy HS, Roberts S, Richardson JB, Wright KT. Chondrogenic potency analyses of donor-matched chondrocytes and mesenchymal stem cells derived from bone marrow, infrapatellar fat pad, and subcutaneous fat. Stem Cells Int 2016; 2016: 6969726 [PMID: 27971068 DOI: 10.1155/2016/6969726]

72 Sakaguchi Y, Sekiya Y, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum 2005; 52: 2521-2529 [PMID: 16052268 DOI: 10.1002/art.21212]

73 Bertolus A, Steffen F, Malonzo-Marty C, Stoyanov J. Canine mesenchymal stem cell potential and the importance of dog breed: implication for cell-based therapies. Cell Transplant 2015; 24: 1969-1980 [PMID: 25357819 DOI: 10.3727/096369814X685294]

74 Van de Walle A, Faisalis W, Wilhem C, Luciani N. Role of growth factors and oxygen to limit hypertrophy and impact of high magnetic nanoparticles dose during stem cell chondrogenesis. Comput Struct Biotechnol J 2018; 16: 532-542 [PMID: 30324668 DOI: 10.2174/1874289X16666180606130114]

75 Augustyniak E, Trzeziak T, Richter M, Kaczmarchzyk J, Suchorska W. The role of growth factors in stem cell-directed chondrogenesis: a real hope for damaged cartilage regeneration. Int Orthop 2015; 39: 995-1003 [PMID: 25521239 DOI: 10.1007/s00264-016-2619-0]

76 Sekiya I, Larson BL, Vuoristo JT, Reger RL, Prockop DJ. Comparison of effect of BMP-2, -4, and -6 on in vitro cartilage formation of human adult stem cells from bone marrow stroma. Cell Tissue Res 2005; 320: 269-276 [PMID: 15778851 DOI: 10.1007/s00264-004-1042-3]

77 Salazar VS, Gammer LW, Rosen V. BMP signalling in skeletal development, disease and repair. Nat Rev Endocrinol 2016; 12: 203-221 [PMID: 26893264 DOI: 10.1038/nrendo.2016.12]

78 Volk SW, Dischendorfer DL, Christopher SA, Haskins ME, Lebey PS. Effects of osteogenic inducers on cultures of canine mesenchymal stem cells. Am J Vet Res 2005; 66: 1729-1737 [PMID: 16273904 DOI: 10.2460/ajvr.2005.66.1729]

79 Nagase T, Muneta T, Ju YJ, Haru K, Morito T, Koga H, Nimura A, Mochizuki T, Sekiya Y. Analysis of the chondrogenic potential of human synovial stem cells according to harvest site and culture parameters in knees with medial compartment osteoarthritis. Arthritis Rheum 2008; 58: 1389-1398 [PMID: 18438859 DOI: 10.1002/art.23418]
Sasaki A et al. MSCs for cartilage regeneration in dogs

80 Ogata Y, Mabuchi Y, Yoshida M, Suto EG, Suzuki N, Muneta T, Sekiya I, Akazawa C. Purified human synovium mesenchymal stem cells as a good resource for cartilage regeneration. PLoS One 2015; 10: e0129096 [PMID: 26013045 DOI: 10.1371/journal.pone.0129096]

81 Shen C, Jiang Y, Zhu B, Le Y, Liu J, Qin Z, Chen H, Zhong G, Zheng L, Zhao J, Zhang X. In vitro culture expansion impairs chondrogenic differentiation and the therapeutic effect of mesenchymal stem cells by regulating the unfolded protein response. J Biol Eng 2018; 12: 26 [PMID: 30479659 DOI: 10.1186/s13036-018-0119-2]

82 Jiang T, Xu G, Wang Q, Yang L, Zhong L, Zhao J, Zhang X. In vitro expansion impaired the sternness of early passage mesenchymal stem cells for treatment of cartilage defects. Cell Discov 2017; 3: e2851 [PMID: 28569773 DOI: 10.1038/cddis.2017.215]

83 Bwalya EC, Wijkeoon HS, Fang J, Kim S, Hossuya K, Okumura M. Independent chondrogenic potential of canine bone marrow-derived mesenchymal stem cells in monolayer expansion cultures decreases in a passage-dependent pattern. J Vet Med Sci 2018; 80: 1681-1687 [PMID: 30210608 DOI: 10.1292/jvms.18-0202]

84 Sekiya I, Colter DC, Prockop DJ. BMP-6 enhances chondrogenesis in a subpopulation of human marrow stromal cells. Biochem Biophys Res Commun 2001; 284: 411-418 [PMID: 11394849 DOI: 10.1016/s0006-291x(01)00489-9]

85 Solchaga LA, Penick K, Goldberg VM, Caplan AI, Welter RF. Fibroblast growth factor-2 enhances proliferation and delays loss of chondrogenic potential in human adult bone-marrow-derived mesenchymal stem cells. Tissue Eng Part A 2010; 16: 1009-1019 [PMID: 19842915 DOI: 10.1089/ten.TEA.2009.0100]

86 El-Toolky, Abou Elkheir W, Mokbel A, Osman A. Intra-articular injection of autologous mesenchymal stem cells in experimental chondral defects in dogs. Egypt Rheumatol 2008; 30: 1-10

87 Mokbel A, El-Toolky O, Shamma AA, Sabry D, Rashid L, Mostafa A. Homing and efficacy of intra-articular injection of autologous mesenchymal stem cells in experimental chondral defects in dogs. Clin Exp Rheumatol 2011; 29: 275-284 [PMID: 21385540 DOI: 10.1088/rrheum.2010.225]

88 Miki S, Takao M, Miyamoto W, Matsuishi T, Kawano H. Intra-articular injection of synovium-derived mesenchymal stem cells with hyaluronic acid can repair articular cartilage defects in a canine model. J Stem Cell Res Ther 2015; 5: 1000314 [DOI: 10.4172/2157-7653.1000314]

89 Duan X, Zhu X, Dong X, Yang J, Huang F, Cen S, Leung F, Fan H, Xiang Z. Repair of large osteochondral defects in a beagle model with a novel type 1 collagen/glycosaminoglycan-porous titanium biphasic scaffold. Mater Sci Eng C Mater Biol Appl 2013; 33: 3951-3957 [PMID: 23910303 DOI: 10.1016/j.msec.2013.05.040]

90 Yun S, Ku SK, Kwon YS. Adipose-derived mesenchymal stem cells and platelet-rich plasma synergistically ameliorate the surgical-induced osteoarthritis in Beagle dogs. J Orthop Surg Res 2016; 11: 9 [PMID: 26768530 DOI: 10.1186/s13018-016-0342-9]

91 Koga H, Shimaya M, Muneta T, Nimura A, Morito T, Hayashi M, Suzuki S, Ju YJ, Mohchizuki T, Sekiya I. Local adherent technique for transplanting mesenchymal stem cells as a potential treatment of cartilage defect. Arthritis Res Ther 2008; 10: R84 [PMID: 18664234 DOI: 10.1080/1076263]

92 Harada Y, Nakasa T, Mahmoud EE, Kamei G, Adachi N, Deie M, Ochi M. Combination therapy with intra-articular injection of mesenchymal stem cells and articularized joint distraction for repair of a chronic osteochondral defect in the rabbit. J Orthop Res 2015; 33: 1466-1473 [PMID: 26174695 DOI: 10.1002/jor.22922]

93 Ozeiki N, Muneta T, Koga H, Nakagawa Y, Mizuno M, Tsuji K, Mabuchi Y, Akazawa C, Kobayashi E, Matsumoto K, Futamura K, Saito T, Sekiya I. Not single but periodic injections of synovial mesenchymal stem cells maintain viable cells in knees and inhibit osteoarthritis progression in rats. Osteoarthritis Cartilage 2016; 24: 1061-1070 [PMID: 26808551 DOI: 10.1016/j.joca.2015.12.018]

94 Grady ST, Britton L, Hinrichs K, Nixon AJ, Watts AE. Persistence of fluorescent nanoparticle-labelled bone marrow mesenchymal stem cells in vitro and after intra-articular injection. J Tissue Eng Regen Med 2019; 13: 191-202 [PMID: 30536848 DOI: 10.1002/term.2781]

95 Park SA, Reilly CM, Wood JA, Chung DJ, Carrade DD, Deremer SL, Seraphin RL, Clark KC, Zwingenberger AL, Borjesson DL, Hayashi K, Russell P, Murphy CJ. Safety and immunomodulatory effects of allogeneic canine adipose-derived mesenchymal stem cells transplanted into the region of the lacrimal gland, the gland of the third eyelid and the knee joint. Cytotherapy 2013; 15: 1498-1510 [PMID: 23992828 DOI: 10.1016/j.jcyt.2013.06.009]

96 Bland SD. Canine osteoarthritis and treatments: a review. Vet Sci Dev 2015; 5: 84-89 [DOI: 10.4081/vsd.2015.5931]

97 Scott RM, Evans R, Conzemius MG. Efficacy of an oral nutraceutical for the treatment of canine osteoarthritis. J Vet Orthop Surg 2011; 34: 312-317 [PMID: 21380218 DOI: 10.1016/j.jvot.2011.04.004]

98 Behshaw Z, Asher L, Dean RS. The attitudes of owners and veterinary professionals in the United Kingdom to the risk of adverse events associated with using non-steroidal anti-inflammatory drugs (NSAIDs) to treat dogs with osteoarthritis. Prev Vet Med Vet Med Sci 2016; 131: 121-126 [PMID: 27544261 DOI: 10.1016/j.prevetmed.2016.07.017]

99 Hofer HR, Tuin RS. Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies. Stem Cell Res Ther 2016; 7: 131 [PMID: 27812948 DOI: 10.1186/s13287-016-0394-0]

100 Toh WS. The emerging role of mesenchymal stem cell secretome in cartilage regeneration. Front Stem Cell Regen Med Res 2017; 4: 3-25 [DOI: 10.2174/174181084771017060003]

101 Nakagawa Y, Muneta T, Kondo S, Mizuno M, Takakuda K, Ichinose S, Tabuchi T, Koga H, Tsuji K, Sekiya I. Synovial mesenchymal stem cells promote healing after meniscal repair in minirnipsins. Osteoarthritis Cartilage 2015; 23: 1007-1017 [PMID: 25683140 DOI: 10.1016/j.joca.2015.02.008]

102 Atesok K, Fu FH, Sekiya Y, Stolzing A, Ochi M, Rodeo SA. Stem cells in degenerative orthopaedic pathologies: effects of aging on therapeutic potential. Knee Surg Sports Traumatol Arthrosc 2017; 25: 626-636 [PMID: 26298714 DOI: 10.1007/s00167-015-3763-9]

103 Guercio A, Di Marco P, Casella S, Cannella V, Russotto L, Paraggi D, Di Bella S, Piccione G. Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints. Cell Biol Int 2012; 36: 189-194 [PMID: 21936851 DOI: 10.1042/CLJ20110304]

104 Vilari JM, Morales M, Santana A, Spinella G, Rubio M, Cuervo B, Cugat R, Carrillo JM. Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs. BMC Vet Res 2013; 9: 131
Sasaki A et al. MSCs for cartilage regeneration in dogs

105 Kriston-Pal E, Czubala Á, Gyuris Z, Balka G, Seregi A, Sikösd F, Súth M, Kiss-Tóth E, Haracska L, Uher F, Monostori E. Characterization and therapeutic application of canine adipose mesenchymal stem cells to treat elbow osteoarthritis. *Can J Vet Res* 2017; 81: 73-78 [PMID: 28197912]

106 Mars C, Silveira MD, Selbach I, da Silva AS, Braga LM, Camassola M, Nardi NB. Acupoint injection of autologous stromal vascular fraction and allogeneic adipose-derived stem cells to treat hip dysplasia in dogs. *Stem Cells Int* 2014; 2014: 391274 [PMID: 25180040 DOI: 10.1155/2014/391274]

107 Black LL, Gaynor J, Adams C, Dhupa S, Sams AE, Taylor R, Harman S, Gingerich DA, Harman R. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. *Vet Ther* 2008; 9: 192-200 [PMID: 19003780 DOI: 10.1007/s11259-008-9105-3]

108 Vilar JM, Batista M, Morales M, Santana A, Cuervo B, Rubio M, Cugat R, Sopena J, Carrillo JM. Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis. *BMC Vet Res* 2014; 10: 143 [PMID: 24984756 DOI: 10.1186/s12917-014-0143-2]

109 Sharkey M. The challenges of assessing osteoarthritis and postoperative pain in dogs. *AAPS J* 2013; 15: 598-607 [PMID: 23456420 DOI: 10.1208/s11248-013-9467-2]

110 Muir P, Hans EC, Racette M, Volstad N, Sample SJ, Heaton C, Holdeman G, Schaefer SL, Bloom DD, Bleedom JA, Hao Z, Amene E, Shresta M, Hematti P. Autologous bone marrow-derived mesenchymal stem cells modulate molecular markers of inflammation in dogs with cruciate ligament rupture. *PLoS One* 2016; 11: e0159095 [PMID: 27575305 DOI: 10.1371/journal.pone.0159095]

111 Kang NH, Park HM. Evaluation of adverse reactions in dogs following intravenous mesenchymal stem cell transplantation. *Acta Vet Scand* 2014; 56: 16 [PMID: 24655411 DOI: 10.1186/1751-0147-56-16]

112 Cimino Brown D. What can we learn from osteoarthritis pain in companion animals? *Clin Exp Rheumatol* 2017; 35 Suppl 107: 53-58 [PMID: 28967360]

113 Fortier LA, Travis AJ. Stem cells in veterinary medicine. *Stem Cell Res Ther* 2011; 2: 9 [PMID: 21371354 DOI: 10.1186/2041-0266-2-9]

114 Kahn D, Mincialedi D, Matsuy J, Qu X, Lee JH, Badar F, Les C, Zhang Z, Xia Y. Meniscus induced cartilaginous damage and non-linear gross anatomical progression of early-stage osteoarthritis in a canine model. *Open Orthop J* 2016; 10: 690-705 [PMID: 28144379 DOI: 10.2174/187432501661016010690]

115 Krier EM, Johnson TA, Breitenreicher AH, Pekyce LE, Hulse DA. Articular cartilage lesions associated with complete lateral meniscal tears in the dog. *Vet Surg* 2018; 47: 958-962 [PMID: 30242838 DOI: 10.1111/vsu.12961]

116 Hart HF, Crossley KM, Felson D, Jarraya M, Guermazi A, Roemer F, Lewis CE, Torner J, Nevitt M, Stefanik JJ. Relation of meniscus pathology to prevalence and worsening of patellofemoral joint osteoarthritis: the Multicenter Osteoarthritis Study. *Osteoarthritis Cartilage* 2018; 26: 912-919 [PMID: 29427724 DOI: 10.1016/j.joca.2017.11.017]

117 Katano H, Koga H, Ozeki N, Otake K, Mizuno M, Tomita M, Muneta T, Sekiya I. Trends in isolated meniscal repair and meniscectomy in Japan, 2011-2016. *Vet Ther* 2016; 47: 297-303 [PMID: 26984756 DOI: 10.1186/1746-6148-10-143]

118 Sullivan MO, Gordon-Evens WJ, Fredericks LP, Kiefer K, Conzemius MG, Griffen DJ. Comparison of mesenchymal stem cell surface markers from bone marrow aspirates and adipose stromal vascular fraction sites. *Front Vet Sci* 2016; 2: 82 [PMID: 26835460 DOI: 10.3389/fvets.2015.00082]

119 Kamishina H, Deng J, Oji T, Cheeseman JA, Clemmons RM. Expression of neural markers on bone marrow-derived canine mesenchymal stem cells. *Am J Vet Res* 2006; 67: 1921-1928 [PMID: 17087756 DOI: 10.2460/ajvr.2006.67.11.1921]

120 Hodgkiss-Goree HM, Argyle DJ, Corcoran BM, Whitelaw B, Milne E, Bennett D, Argyle SA. Characterisation and differentiation potential of bone marrow derived canine mesenchymal stem cells. *Vet J* 2012; 194: 361-368 [PMID: 22721628 DOI: 10.1016/j.jvetmeda.2012.05.011]

121 Black LL, Gaynor J, Gahring D, Adams C, Aron D, Harman S, Gingerich DA, Harman R. Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. *Vet Ther* 2007; 8: 272-284 [PMID: 18138546 DOI: 10.1111.j.1522-950X.2007.00340.x]

122 Cuervo B, Rubio M, Sopena J, Dominguez JM, Vilar J, Morales M, Cugat R, Carrillo JM. Hip osteoarthritis in dogs: a randomized study using mesenchymal stem cells from adipose tissue and plasma rich in growth factors. *Int J Mol Sci* 2014; 15: 13437-13460 [PMID: 25080977 DOI: 10.3390/ijms15081347]

123 Harman R, Carlson K, Gaynor J, Gustafson S, Dhupa S, Clement K, Hoelzler M, McCarthy T, Schwartz P, Adams C. A prospective, randomized, masked, and placebo-controlled efficacy study of intraarticular allogeneic adipose stem cells for the treatment of osteoarthritis in dogs. *Front Vet Sci* 2016; 3: 81 [PMID: 27605608 DOI: 10.3389/fvets.2016.00081]

124 Shah K, Drury T, Roie I, Hansen P, Malin M, Boyd R, Sumer H, Ferguson R. Outcome of allogeneic adult stem cell therapy in dogs suffering from osteoarthritis and other joint defects. *Stem Cells Int* 2018; 2018: 739201 [PMID: 30050478 DOI: 10.1155/2018/739201]
